---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096627"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:23:04.529488+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics Q2 net loss $54.9M; completed Tenet Medicines acquisition and $120M financing

## Summary
- Completed acquisition of Tenet Medicines and concurrent $120M private placement in June 2024.
- Cash and equivalents $223.1M as of June 30, expected to fund operations into 2027.
- Net loss of $54.9M for Q2 2024 vs $5.2M in Q2 2023, largely due to $51.7M acquired IP R&D expense.
- Lead product budoprutug (anti-CD19) targets autoimmune diseases including lupus and immune thrombocytopenia.
- Appointed Aoife Brennan as CEO and Jan Hillson as Senior Clinical Advisor; added to Russell 2000 index.

## SEC filing metadata
- accession: 0000950170-24-096627
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017024096627/0000950170-24-096627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017024096627/elym-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096627
- JSON: https://secwatch.observer/filing/0000950170-24-096627.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.